Mattsson C, Hoylaerts M, Holmer E, Uthne T, Collen D
J Clin Invest. 1985 Apr;75(4):1169-73. doi: 10.1172/JCI111812.
Clinical grade heparin is a very heterogeneous mucopolysaccharide, containing molecules with Mr ranging from 6,000 to 30,000 that have either a high affinity or a low affinity for antithrombin III (AT). In this study, the antithrombotic properties of intact high-affinity heparin (Mr = 15,000) and of two heparin fragments (h16, a 16-monosaccharide fragment, with Mr = 4,300, and h12, a 12-monosaccharide fragment, with Mr = 3,200) and of their functional covalent stoichiometric complexes with human AT were compared in a venous thrombosis stasis model in rabbits. Thrombosis was induced by injection of glass-activated human plasma and measured in a segment of the jugular vein that was isolated between two vascular clamps for 10 min. Injections of 55 micrograms/kg resulted in a clear antithrombotic effect for intact heparin, but not for the two fragments. Equivalent amounts (carbohydrate moiety) of covalent complexes of heparin or of both heparin fragments with human AT resulted in an antithrombotic effect lasting for 45-60 min. Injection of 110 micrograms/kg of heparin and of the heparin fragments yielded an antithrombotic effect, lasting 45-60 min; the corresponding amounts of covalent complexes caused an anti-thrombotic effect for 60-120 min. The free and conjugated fragments produced equal antithrombotic effects at equal plasma levels of anti-Factor Xa activity, but the specific antithrombotic activities of free and complexed intact heparin, on a molar basis, were 10-20-fold greater than those of the free and complexed heparin fragments. The plasma half-life of the covalent complexes of the heparin fragments with AT is, however, 10 times longer than that of the complex between intact heparin and AT and 30 times longer than that of free intact heparin. Covalent complexes between AT and heparin fragments could, therefore, be useful to maintain more stable levels of antithrombotic activity in plasma.
临床级肝素是一种非常不均一的粘多糖,其分子质量(Mr)范围为6000至30000,对抗凝血酶III(AT)具有高亲和力或低亲和力。在本研究中,在兔静脉血栓形成淤滞模型中比较了完整的高亲和力肝素(Mr = 15000)、两种肝素片段(h16,一种16单糖片段,Mr = 4300;h12,一种12单糖片段,Mr = 3200)及其与人AT的功能性共价化学计量复合物的抗血栓形成特性。通过注射玻璃激活的人血浆诱导血栓形成,并在两个血管夹之间分离10分钟的一段颈静脉中进行测量。注射55微克/千克对完整肝素产生明显的抗血栓形成作用,但对两种片段则无此作用。肝素或两种肝素片段与人AT的共价复合物的等量(碳水化合物部分)产生持续45至60分钟的抗血栓形成作用。注射110微克/千克的肝素和肝素片段产生持续45至60分钟的抗血栓形成作用;相应量的共价复合物引起60至120分钟的抗血栓形成作用。在抗Xa因子活性的血浆水平相等时,游离和结合的片段产生相等的抗血栓形成作用,但以摩尔为基础,游离和复合完整肝素的比抗血栓形成活性比游离和复合肝素片段的比抗血栓形成活性大10至20倍。然而,肝素片段与AT的共价复合物的血浆半衰期比完整肝素与AT之间的复合物的血浆半衰期长10倍,比游离完整肝素的血浆半衰期长30倍。因此,AT与肝素片段之间的共价复合物可能有助于在血浆中维持更稳定的抗血栓形成活性水平。